What should you know about NHT for prostate cancer?

NHT is a group of medicines used as part of prostate cancer treatment. These medicines interfere with androgen signalling. Androgens, including testosterone, can stimulate some prostate cancer cells; reducing that signal can slow their activity or growth. NHT is different from surgery to remove the prostate and from radiotherapy, although a care plan may combine treatments.

The choice may be influenced by whether the cancer is confined to the prostate, has returned after earlier treatment, or has spread beyond it. Your oncology team may also consider previous treatments, other health conditions, medicines, and your priorities. Treatment can involve monitoring, scans, blood tests, and discussion of symptoms alongside the medicine itself.

Ask which medicine is being offered, why it is suitable for your cancer, how it will be taken, and how your team will assess its effect. Share your full medicine list, including supplements, because interactions and overlapping side effects can affect the plan. Keep appointments for blood tests or imaging, and report new or worsening symptoms rather than stopping treatment on your own.

Possible effects vary by medicine and person. Your team may discuss tiredness, hot flushes, changes in sexual function, mood changes, and effects on bones, muscles, or heart health. Practical support can include activity advice, emotional support, and treatment for symptoms. If prostate cancer affects the bones, ask whether bone-strengthening therapy is relevant to you.

Contact your oncology team promptly for severe or rapidly worsening pain, new weakness or numbness, trouble walking, loss of bladder or bowel control, fever, chest pain, breathlessness, or a sudden severe change in your general condition. These symptoms need timely assessment because prostate cancer or its treatment can affect different parts of the body.

Seek urgent help for inability to pass urine, severe breathing difficulty, fainting, or sudden weakness on one side. Difficulty passing urine can have several causes, so it should be assessed rather than attributed to cancer or NHT without an examination.

Useful questions include: What is the aim of NHT in my situation? Will I receive another treatment with it? Which symptoms should I record? How might it affect my other health conditions or medicines? What monitoring will I need, and who should I contact outside appointments? If treatment options include surgery or radiation, how do their goals and possible effects compare for me?